11 completed, 4 unknown, 4 withdrawn, 3 terminated. 9 Not applicable, 8 Phase 2, 6 Phase 1, 1 Early Phase 1, 1 Phase 3.
Follow this drug Literature Review of Antigens, Dermatophagoides trials Research Report on Antigens, Dermatophagoides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Sublingual Immunotherapy for Allergic Rhinitis Due to House Dust Mites Sublingual Film for Dermatophagoides pteronyssinus, Sublingual Film for Dermatophagoides pteronyssinus placebo - Allergic Rhinitis Due to Dust Mite | Phase 2 | Not yet recruiting | Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 250 | 2026-03-23 | 2026-03-16 |
| Dupilumab Effects Against Aeroallergen Challenge Dupilumab, House Dust Mites (HDM), Placebo - Asthma, Allergic | Phase 2 | Active not recruiting | The University of Texas Health Science Center at San Antonio | 96 | 2023-03-29 | 2026-08-11 |
| Interest of Nasal Provocation Tests for Diagnosis of House Mites Allergic Rhinitis Nasal provocation test - 725 Dermatophagoides Pteronyssinus, Negative control - Mite Allergy, Respiratory Disease | Phase 4 | Terminated | Centre Hospitalier Régional Metz-Thionville | 8 | 2022-03-07 | 2024-08-09 |
| Impact of Carrier Solutions for House Dust Mite Allergen on Allergic Reactions Sodium chloride particles, Lactose particles, Clean air - Allergic Rhinitis | Not applicable | Completed | Fraunhofer-Institute of Toxicology and Experimental Medicine | 19 | 2022-02-22 | 2024-10-15 |
| Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients House Dust Mite Extract, Dermatophagoides Farinae - Mite Allergy, Rhinitis, Allergic | Phase 1 | Unknown | RAPHAS | 54 | 2022-01-20 | 2024-04-10 |
| Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae, Placebo - House Dust Mite Allergy | Phase 3 | Unknown | Probelte Pharma S.L.U. | 350 | 2022-01-17 | 2024-07-18 |
| Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients House Dust Mite Allergen, Allergen-free air - Atopic Dermatitis, House Dust Mite Allergy | Not applicable | Completed | Fraunhofer-Institute of Toxicology and Experimental Medicine | 23 | 2021-09-10 | 2024-10-15 |
| Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma Dermatophagoides pteronyssinus allergen, Blood sampling, Bronchial challenge with allergen - Allergic Asthma, Severe Eosinophilic Asthma | Not applicable | Unknown | Lithuanian University of Health Sciences | 80 | 2020-10-01 | 2020-09-09 |
| Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation Anakinra, Anakinra Matching Placebo, Dermatophagoides Farinae - Asthma | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2020-09-01 | 2021-05-14 | |
| Anakinra as a Rescue Treatment for Allergic Inflammation Anakinra, Preservative-free 0.9% sodium chloride (Placebo), House dust mite allergen - Asthma, Allergic | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-12-16 | 2022-06-08 | |
| Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation Anakinra, Anakinra Matching Placebo, Dermatophagoides Farinae - Asthma | Phase 1 / Phase 2 | Withdrawn | University of North Carolina, Chapel Hill | 2019-08-09 | 2021-05-07 | |
| Screening Inhaled Allergen Challenge for Dermatophagoides Farinae Der f - Asthma | Early Phase 1 | Terminated | University of North Carolina, Chapel Hill | 14 | 2018-01-29 | 2022-10-18 |
| House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance House dust mite - Allergic Asthma | Not applicable | Withdrawn | China Medical University Hospital | 2017-11-30 | 2021-08-02 | |
| Role of Extracellular Matrix in the Development of Airway Remodeling in Asthma Bronchial challenge with allergen, Co-culture formation, Inhibition of Wnt and Smad signaling pathways - Allergic Asthma, Airway Remodelling | Not applicable | Unknown | Lithuanian University of Health Sciences | 60 | 2017-06-01 | 2020-09-07 |
| AsthMatic Inflammation and Neurocircuitry Activation (MINA) Whole lung antigen challenge, segmental allergen challenge - Allergic Asthma | Completed | University of Wisconsin, Madison | 43 | 2016-07-28 | 2021-02-16 | |
| Bronchial Allergen Provocation Tests in Asthmatics in Guangzhou house dust mites - Allergic Asthma | Not applicable | Completed | Guangzhou Institute of Respiratory Disease | 30 | 2015-07-01 | 2018-02-19 |
| Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction. house dust mite and alternaria allergen bronchial challenge - House Dust Mite Allergy, Bronchial Hyperresponsiveness | Not applicable | Completed | Johann Wolfgang Goethe University Hospital | 425 | 2011-01-01 | 2023-03-13 |
| Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis Pangramin Plus D. pteronyssinus, Placebo - Local Allergic Rhinitis | Phase 2 | Completed | Miguel Blanca Gomez | 36 | 2010-01-01 | 2016-03-31 |
| Distinct Response of CD4+CD25+Foxp3+ and IL-10-secreting Type I T Regulatory Cells to Cluster Specific Immunotherapy in Allergic Rhinitis Children Dermatophagoides pteronyssinus, Pharmacotherapy - Allergic Rhinitis, Effects of Immunotherapy | Not applicable | Completed | Beijing Tongren Hospital | 50 | 2009-02-01 | 2011-02-08 |
| A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10), House dust mite allergen extract in combination with CYT003-QbG10-placebo - Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy | Phase 2 | Completed | Cytos Biotechnology AG | 100 | 2007-11-01 | 2009-04-27 |
Showing 20 of 24. Sign in to see all of them.
Asthma (10) · Dust Mite Allergy (7) · Hypersensitivity (3) · Rhinitis, Allergic (3) · Bronchial Hyperreactivity (2) · Airway Remodeling (1) · Dermatitis, Atopic (1) · Pulmonary Eosinophilia (1) · Respiration Disorders (1)
University of North Carolina, Chapel Hill (5) · Cytos Biotechnology AG (2) · Fraunhofer-Institute of Toxicology and Experimental Medicine (2) · Lithuanian University of Health Sciences (2) · Beijing Tongren Hospital (1) · Centre Hospitalier Régional Metz-Thionville (1) · China Medical University Hospital (1) · Guangzhou Institute of Respiratory Disease (1) · Johann Wolfgang Goethe University Hospital (1) · John Sundy (1) · Miguel Blanca Gomez (1) · National Institute of Environmental Health Sciences (NIEHS) (1) · Probelte Pharma S.L.U. (1) · RAPHAS (1) · The University of Texas Health Science Center at San Antonio (1)
United States (6) · China (3) · Germany (3) · Lithuania (2) · Spain (2) · France (1) · South Korea (1) · Switzerland (1)
Michelle Hernandez, MD (3) · Jens M Hohlfeld, Prof. Dr. (2) · Philipp Mueller, MD (2) · David B Peden, MD, MS (1) · Jinping Zheng (1) · Johannes Schulze, Dr. (1) · John S Sundy, M.D., PhD. (1) · Luo Zhang, M.D (1) · Michelle Hernandez (1) · Miguel Blanca, MD, PhD (1) · Sundy S. Sundy, MD. PhD. (1) · Sunil K Ahuja, MD (1) · William Busse, MD (1)
PMID 21729182, PMID 23331526, PMID 27008542, PMID 31438916, PMID 31885750, PMID 34199925
R01HL135235 (4), 2008 (1), 2018 (1), R01HL123284 (1), U01AI158460 (1)